Trial Filter
BETAAn intelligent search tool for clinical trials
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Eligibility Criteria
Inclusion Criteria
- 1Histologically and/or cytologically confirmed adenocarcinoma of the colon or rectum which is locally advanced unresectable or metastatic
- 2Able to provide the most recently available formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks (or freshly sectioned slides) obtained prior to treatment initiation to a central laboratory
- 3If archival tissue is not available, a newly-obtained baseline biopsy of an accessible tumor lesion is required within 35 days prior to start of study treatment
- 4HER2+ disease as determined by a tissue based assay performed at a central laboratory.
- 5Participant has rat sarcoma viral oncogene homolog wild-type (RAS WT) disease as determined by local or central testing. For central RAS analysis, tissue sample must be analyzed within 1 year of biopsy date.
- 6Radiographically measurable disease per RECIST v1.1 with:
- 7At least one site of disease that is measurable and that has not been previously irradiated, or
- 8If the participant has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
- 9Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- 10CNS Inclusion - based on contrast brain magnetic resonance imaging, participants may have any of the following:
- 11No evidence of brain metastases
- 12Previously treated brain metastases which are asymptomatic
Exclusion Criteria
- 1Prior systemic anticancer therapy for colorectal cancer (CRC) in the locally advanced unresectable or metastatic setting; note that participants may have received a maximum of 2 doses of mFOLFOX6 in the locally advanced/unresectable or metastatic setting prior to randomization.
- 2Note: May have received chemotherapy for CRC in the adjuvant setting if it was completed \>6 months prior to enrollment
- 3Radiation therapy within 14 days prior to enrollment (or within 7 days in the setting of stereotactic radiosurgery)
- 4Previous treatment with anti-HER2 therapy
- 5Ongoing Grade 3 or higher neuropathy
- 6Active or untreated gastrointestinal (GI) perforation at the time of screening.
Locations
378 sites participating in this study
Emory University Hospital Midtown
Atlanta, Georgia 30308
Emory University Hospital
Atlanta, Georgia 30322
Winship Cancer Institute
Atlanta, Georgia 30322